The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Alexander Perl, University of Pennsylvania, Philadelphia, US. We asked, Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?

Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?

Perl reports the results from a retrospective study evaluating clinical outcomes in patients with relapsed or refractory AML treated with midostaurin or sorafenib before receiving gilteritinib in the CHRYSALIS trial and in the ADMIRAL trial.

Share: